With the collapse of Senate Republicans' efforts to repeal and replace the Patient Protection and Affordable Care Act (PPACA), President Donald Trump declared that his plan now was to “let Obamacare fail.”
An increasing trend of resistance to drugs that fight human immunodeficiency virus (HIV) could undermine global progress in treating and preventing the infection if early and effective action is not taken, warns the World Health Organization (WHO).
Employers should do their best to accommodate workers with disabilities or who are recovering from injuries, but there’s been little change in the total unemployment numbers of such workers since the passage of the Americans With Disabilities Act in 1990, Workforce reports.
A phase 3 trial of an oral formulation of Paratek Pharmaceuticals’ antibiotic omadacycline has met its primary endpoints, FierceBiotech reports. The third late-phase success for omadacycline sets Paratek up to file for approval with the FDA, although incidence of vomiting and nausea cast a shadow over the data.
The FDA has approved the first extended adjuvant therapy for early-stage, HER2-positive breast cancer. To further lower the risk of the cancer coming back, neratinib (Nerlynx, Puma Biotechnology Inc.) is indicated for adults who have previously been treated with a regimen that includes the drug trastuzumab (Herceptin, Genentech).
At least one health plan nudges the value-based payment system toward an approach that many experts believe has to happen if the scheme is to succeed. Most value-based payment systems reward doctors for keeping costs down, but don’t detract from their pay if costs go up.
UnitedHealth Group’s net profit for the second quarter rose to $2.28 billion, or $2.32 a share, from $1.75 billion, or $1.81 a share, in last year’s second quarter, the Wall Street Journal reports. Profit from premiums rose from $36.4 billion to $39.4 billion, according to experts.